CD44 and ductal breast carcinoma in situ: In this study, by applying a novel single-cell clonogenic approach with the CD49f+/CD44+/CD24− surface markers, we characterized the aggressive clones that have enhanced self-renewal, migratory and invasive capacities derived from a human DCIS model cell line MCF10DCIS.